Method for Synthesizing Pitavastatin t-Butyl Ester A method for synthesizing pitavastatin tert-butyl ester includes obtaining a substance B through reacting (4R-CIS)-6-chloromethyl-2,2-dimethyl-1,3-dioxolane-4-acetic acid tert-butyl ester with a substance A under the action of a first base catalyst, 5 oxidizing with an oxidizing agent to obtain a substance C, then reacting with 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-formaldehyde under the action of a second base catalyst to obtain a substance D, and finally, carrying out an acid deprotection to obtain pitavastatin t-butyl ester. The reaction conditions of the present invention are mild and controllable, and the reaction conditions of the synthesis of the Julia olefination do 10 not require an ultra-low temperature reaction. The operation is convenient and simple, the stereoselectivity is good, the yield is high, and the synthesized pitavastatin t-butyl ester is a completely non-cis isomer, and its purity is high.

Method for Synthesizing Pitavastatin t-Butyl Ester A method for synthesizing pitavastatin tert-butyl ester includes obtaining a substance B through reacting (4R-CIS)-6-chloromethyl-2,2-dimethyl-1,3-dioxolane-4-acetic acid tert-butyl ester with a substance A under the action of a first base catalyst, 5 oxidizing with an oxidizing agent to obtain a substance C, then reacting with 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-formaldehyde under the action of a second base catalyst to obtain a substance D, and finally, carrying out an acid deprotection to obtain pitavastatin t-butyl ester. The reaction conditions of the present invention are mild and controllable, and the reaction conditions of the synthesis of the Julia olefination do 10 not require an ultra-low temperature reaction. The operation is convenient and simple, the stereoselectivity is good, the yield is high, and the synthesized pitavastatin t-butyl ester is a completely non-cis isomer, and its purity is high.

The present disclosure relates to a hydrothermally stable catalyst composition. The hydrothermally stable supported catalyst composition comprises K.sub.2CO.sub.3 impregnated on an amorphous silica-alumina support. The weight ratio of silica to alumina in the support is in the range of 0.1 to 1.5. The amount of K.sub.2CO.sub.3 is in the range of 5 wt % to 60 wt % with respect to the total catalyst composition. The catalyst composition is characterized by a pore volume in the range of 0.1 cc/g to 0.9 cc/g, a surface area in the range of 40 m.sup.2/g to 250 m.sup.2/g and an attrition index in the range of 2% to 8%. The present disclosure also relates to a process for preparing the catalyst composition. The catalyst composition provides improved hydrothermal stability, attrition resistance, high pore volume and surface area for gasifying carbonaceous feed at low temperature, as compared to a conventional catalyst composition.

The present disclosure relates to a hydrothermally stable catalyst composition. The hydrothermally stable supported catalyst composition comprises K.sub.2CO.sub.3 impregnated on an amorphous silica-alumina support. The weight ratio of silica to alumina in the support is in the range of 0.1 to 1.5. The amount of K.sub.2CO.sub.3 is in the range of 5 wt % to 60 wt % with respect to the total catalyst composition. The catalyst composition is characterized by a pore volume in the range of 0.1 cc/g to 0.9 cc/g, a surface area in the range of 40 m.sup.2/g to 250 m.sup.2/g and an attrition index in the range of 2% to 8%. The present disclosure also relates to a process for preparing the catalyst composition. The catalyst composition provides improved hydrothermal stability, attrition resistance, high pore volume and surface area for gasifying carbonaceous feed at low temperature, as compared to a conventional catalyst composition.

Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.

Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.

A nitrogen oxide storage material comprising: Mg.sub.1−yAl.sub.2O.sub.4−y, wherein y is a number satisfying 0≤y≤0.2, a noble metal, an oxide of a metal other than the noble metal, and a barium compound, the noble metal, the oxide, and the barium compound being loaded on Mg.sub.1−yAl.sub.2O.sub.4−y. The metal oxide comprises at least one metal oxide selected from zirconium oxide, praseodymium oxide, niobium oxide, and iron oxide.

A nitrogen oxide storage material comprising: Mg.sub.1−yAl.sub.2O.sub.4−y, wherein y is a number satisfying 0≤y≤0.2, a noble metal, an oxide of a metal other than the noble metal, and a barium compound, the noble metal, the oxide, and the barium compound being loaded on Mg.sub.1−yAl.sub.2O.sub.4−y. The metal oxide comprises at least one metal oxide selected from zirconium oxide, praseodymium oxide, niobium oxide, and iron oxide.

Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.

Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.